Chronic Anal Fissure (>8 Weeks)
Investigational idea for chronic anal fissure refractory to medical therapy; no clinical study identified; sphincterotomy remains the gold standard.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for anal fissures. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for chronic anal fissures is investigational and considered high-infection-risk.
- What evidence exists?
- Tier C (investigational). No clinical study or case report of leech therapy for anal fissure was identified; there are no randomized controlled trials. Evidence-based therapy for chronic anal fissures per ASCRS guidelines: fiber supplementation and sitz baths, topical nitroglycerin 0.2-0.4% or topical nifedipine, botulinum toxin injection, and lateral internal sphincterotomy (gold standard for refractory disease, >90 percent cure). The perianal area is high-risk for bacterial superinfection of any breach in the skin barrier.
- Main risks
- Severe infection risk from leech placement in the perianal area (fecal flora)
- Bleeding from bite sites that may obscure fissure-related bleeding
- Local skin infection or, rarely, Aeromonas infection in a contaminated area
- Worsening of fissure pain from procedure-related trauma
- Anal abscess or fistula formation
- Allergic reaction to leech saliva (uncommon)
- Delay of evidence-based topical nitroglycerin, nifedipine, botulinum toxin, or sphincterotomy
- Risk of missed underlying inflammatory bowel disease or anorectal malignancy
- Who should not consider this
- Patients with active perianal infection, abscess, or fistula
- Patients with inflammatory bowel disease (Crohn perianal disease)
- Patients with suspected anorectal malignancy
- Patients with HIV or immunocompromise (severe infection risk)
- Patients on anticoagulants, with hemophilia, or with anemia
- Patients who have not tried topical nitroglycerin or nifedipine
- Patients who have not been evaluated by a colorectal surgeon
- What to ask your clinician
- Has inflammatory bowel disease or anorectal malignancy been ruled out?
- Have I tried fiber supplementation, sitz baths, and topical nitroglycerin or nifedipine?
- Am I a candidate for botulinum toxin injection or lateral internal sphincterotomy (>90 percent cure)?
- What is the realistic infection risk from leech placement in the perianal area?
- What evidence specifically supports leech therapy for anal fissures?
- What is the practitioner's antibiotic and infection-control protocol?
- What is the cost and is it covered by insurance? (typically not covered)
- When to seek urgent care
- Severe perianal pain with fever (possible anal abscess — surgical emergency)
- Persistent rectal bleeding, mucus, or pus
- New incontinence or inability to control bowel movements
- Spreading redness, warmth, pus, or red streaks (cellulitis or abscess)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
What this does NOT mean
- This is NOT FDA-cleared for anal fissures.
- With no clinical study at all, there is NO evidence of efficacy versus topical nitroglycerin, nifedipine, botulinum toxin, or lateral internal sphincterotomy.
- It does NOT substitute for evidence-based pharmacologic or surgical therapy.
- It does NOT mean perianal leech application is safe — fecal flora and abscess risk are real.
- It does NOT replace colorectal surgical evaluation when standard therapy fails.
Safety cross-references
Clinical Profile
- Category
- Gastrointestinal
- ICD-10
- K60.1
- Safety tier
- Medium
Evidence Summary
Chronic anal fissure (>8 weeks) is conventionally treated with topical glyceryl trinitrate or diltiazem (roughly 50-60% healing), botulinum toxin injection (roughly 60-70% healing), and lateral internal sphincterotomy (the gold standard, >90% healing but with about a 10% risk of minor incontinence). No clinical study or case report of leech therapy for anal fissure was identified in PubMed, Europe PMC, ClinicalTrials.gov, the Baskova and Isakhanyan (2004) monograph, or English, Russian and German web searches; the rationale is mechanistic only, and use for this indication is investigational. Sphincter manometry and proctologic evaluation are appropriate before considering any complementary therapy, and IBD-related fissures require gastroenterology management.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Posterior or lateral atypical fissure (workup for IBD, malignancy)
- Active perianal abscess or fistula
- Crohn's disease perianal manifestation
- Prior anal sphincter surgery with incontinence
Related Conditions
Hemorrhoids (Grade II-III, Symptomatic)
Investigational use for symptomatic relief of grade II-III internal/external hemorrhoidal disease; does not address anatomic prolapse.
Coccydynia (Chronic)
Investigational use for chronic coccyx pain after fall, childbirth, or idiopathic onset; no clinical study of leech therapy was identified.
Non-Alcoholic Fatty Liver Disease (Investigational Adjunct)
Investigational adjunct in NAFLD/MASLD; no human clinical study identified; weight loss, dietary modification, and resmetirom remain primary.
Hepatic Portal Congestion (Non-Cirrhotic, Investigational)
Highly investigational adjunct for non-cirrhotic hepatic congestion; uncontrolled Russian series only; cirrhosis and portal hypertension are absolute exclusions.